View Older Stories View More Recent Stories

Dec 9, 2021 09:07AM AbbVie (ABBV) Announces VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision, is Now Available
Dec 9, 2021 09:00AM VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available
Dec 6, 2021 08:31AM AbbVie's (ABBV) Upadacitinib Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study
Dec 6, 2021 08:30AM Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease
Dec 3, 2021 04:16PM AbbVie's (ABBV) Label for RINVOQ for the Treatment of Rheumatoid Arthritis Will Include Additional Cardiac Risk Info
Dec 3, 2021 04:15PM AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.
Nov 30, 2021 08:06AM AbbVie (ABBV) Submits Application for Risankizumab to the EMA
Nov 30, 2021 08:05AM AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)
Nov 23, 2021 08:15AM AbbVie to Present at the Evercore ISI Conference
Nov 23, 2021 08:00AM AbbVie to Present at the Piper Sandler Healthcare Conference
Nov 19, 2021 08:00AM Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting
Nov 18, 2021 09:00AM New Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission
Nov 17, 2021 05:06AM AbbVie (ABBV) Announces European Commission Approval of SKYRIZI
Nov 17, 2021 02:05AM AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis
Nov 15, 2021 08:30AM Allergan Aesthetics Celebrates Third Annual BOTOX® Cosmetic (onabotulinumtoxina) Day
Nov 10, 2021 08:30AM AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025
Nov 10, 2021 08:00AM AbbVie to Present at the Wolfe Research Healthcare Conference
Nov 9, 2021 08:45AM AbbVie (ABBV) Reports New Efficacy Data on Upadacitinib in People with Active Psoriatic Arthritis
Nov 9, 2021 08:45AM AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021
Nov 9, 2021 08:31AM AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis
Nov 8, 2021 08:30AM Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting
Nov 5, 2021 10:06AM AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021
Nov 4, 2021 09:06AM Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
Nov 4, 2021 09:05AM Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
Nov 4, 2021 09:05AM AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting
Nov 1, 2021 08:31AM AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021
Oct 29, 2021 05:33PM AbbVie (ABBV) Announces FDA Approval of VUITY 1.25%, the First and Only Eye Drop to Treat Presbyopia
Oct 29, 2021 05:31PM U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)
Oct 29, 2021 07:51AM AbbVie's (ABBV) Cariprazine Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
Oct 29, 2021 07:50AM AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
Oct 29, 2021 07:40AM AbbVie Reports Third-Quarter 2021 Financial Results
Oct 28, 2021 08:19AM AbbVie (ABBV) Reports ABBV-951Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial
Oct 28, 2021 08:15AM AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advan
Oct 26, 2021 08:30AM Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia
Oct 15, 2021 08:35AM AbbVie (ABBV) Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union
Oct 15, 2021 08:35AM AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
Oct 11, 2021 08:42AM Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness
Oct 7, 2021 08:16AM AbbVie (ABBV) Announces RINVOQ (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
Oct 7, 2021 08:16AM AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
Oct 7, 2021 08:15AM AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
Oct 5, 2021 08:00AM AbbVie to Host Third-Quarter 2021 Earnings Conference Call
Oct 2, 2021 06:06PM AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021
Sep 30, 2021 09:45AM AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress
Sep 30, 2021 08:39AM AbbVie (ABBV) Presents New Analyses Evaluating RINVOQ in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
Sep 30, 2021 08:30AM AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
Sep 29, 2021 06:17AM AbbVie (ABBV) Announces FDA Approves QULIPTA, First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine
Sep 28, 2021 06:42PM FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine
Sep 27, 2021 08:30AM Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals
Sep 23, 2021 08:45AM AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress
Sep 20, 2021 09:10AM AbbVie (ABBV) Submits Regulatory Application to FDA for Risankizumab-rzaa for Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
View More Recent Stories View Older Stories